Development of a novel class of tubulin inhibitors with promising anticancer activities

Molecular Cancer Research

Volumn 11, Issue 8, 2013, Pages 856-864

  Xi, Jingle ^a,b,d   Zhu, Xuejun ^c,e   Feng, Yongmei ^c   Huang, Na ^d   Luo, Guifen ^a,b   Mao, Yongjun ^a,b   Han, Xiaofeng ^a,b   Tian, Wang ^a,b   Wang, Guirong ^b   Han, Xiaobing ^a,b   Luo, Rongcheng ^d   Huang, Ziwei ^a,b   An, Jing ^a,b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c BURNHAM INSTITUTE   (United States)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

^e CHINA NATIONAL CHEMICAL CORPORATION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; ANTINEOPLASTIC AGENT; COLCHICINE; MHA 1; MHA 11; MHA 6; PROTEIN INHIBITOR; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DNA DETERMINATION; DNA FRAGMENTATION; DRUG CYTOTOXICITY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; IC 50; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; MASS SPECTROMETRY; MICROTUBULE; MICROTUBULE ASSEMBLY; MOLECULAR DOCKING; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL;

ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOPYRANS; BINDING SITES; BONE MARROW CELLS; CELL LINE, TUMOR; COLCHICINE; DNA FRAGMENTATION; DRUG DISCOVERY; G2 PHASE; HL-60 CELLS; HUMANS; MICROTUBULES; MOLECULAR DOCKING SIMULATION; NITRILES; TUBULIN; TUBULIN MODULATORS;

EID: 84882777344     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0177     Document Type: Article

References (29)

1. Lopez-Fanarraga M, Avila J, Guasch A, Coll M, Zabala JC. Review: postchaperonin tubulin folding cofactors and their role in microtubule dynamics. J Struct Biol 2001;135:219-29.
2. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev 2009; 28:5-14.
3. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
4. Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev 2009;35:255-61.
5. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8:413-50.
6. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65-71.
7. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Revs Drug Discov 2010;9:790-803.
8. Carlson RO. New tubulin targeting agents currently in clinical development. Expert Opin Investig Drugs 2008;17:707-22.
9. Perez EA. Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther 2009;8:2086-95.
10. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008;14:7167-72.
11. Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells? J Cell Sci 2009;122:2579-85.
12. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 2000;97:7124-9.
13. An J, Chen Y, Huang Z. Critical upstream signals of cytochrome c release induced by a novel Bcl-2 inhibitor. J Biol Chem 2004; 279:19133-40.
14. Risinger AL, Westbrook CD, Encinas A, Mülbaier M, Schultes CM, Wawro S, et al. ELR510444, a novel microtubule disruptor with multiple mechanisms of action. J Pharmacol Exp Ther 2011;336: 652-60.
15. LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, et al. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther 2008;7: 1472-82.
16. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428:198-202.
17. Kitazumi I, Tsukahara M. Regulation of DNA fragmentation: the role of caspases and phosphorylation. FEBS J 2011;278:427-41.
18. An J, Nie A, Chervin A, Ducoff HS, Huang Z. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 2007;26:652-61.
19. Manero F, Gautier F, Gallenne T, Cauquil N, Gree D, Cartron PF, et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 2006;66:2757-64.
20. Sinicrope FA, Penington RC, Tang XM. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor,HA14-1, in human colon cancer cells. Clin Cancer Res 2004;10:8284-92.
21. Campas C, Cosialls AM, Barragan M, Iglesias-Serret D, Santidrian AF, Coll-Mulet L, et al. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp Hematol 2006;34:1663-9.
22. Hermanson D, Addo SN, Bajer AA, Marchant JS, Das SG, Srinivasan B, et al. Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria. Mol Pharmacol 2009;76: 667-78.
23. Yue QX, Liu X, Guo DA. Microtubule-binding natural products for cancer therapy. Planta Med 2010;76:1037-43.
24. Fojo AT, Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005;32:S3-8.
25. Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, et al. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-Tubulin. Mol Cancer Ther 2004;3:1319-27.
26. Kanakkanthara A, Wilmes A, O'Brate A, Escuin D, Chan A, Gjyrezi A, et al. Peloruside-And laulimalide-resistant human ovarian carcinoma cells have betaI-Tubulin mutations and altered expression of betaIIand betaIII-Tubulin isotypes. Mol Cancer Ther 2011;10:1419-29.
27. Wilmes A, O'Sullivan D, Chan A, Chandrahasen C, Paterson I, Northcote PT, et al. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells. Cancer Chemother Pharmacol 2011;68:117-26.
28. Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA. Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. Int J Cancer 2010; 126:743-55.
29. Yardley DA, Raefsky E, Castillo R, Lahiry A, Locicero R, Thompson D, et al. Phase II study of neoadjuvant weekly nab-Paclitaxel and Carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2(+) breast cancer. Clin Breast Cancer 2011;11:297-305.